Quick answer
There is no single price for “cancer treatment”. What can be compared is the cost of each phase. In China, a lobectomy at a tertiary public hospital is commonly quoted at $4,300–11,400 (30,000–80,000 yuan), a chemotherapy cycle at $430–1,430, and a radiotherapy course at $1,400–4,300. The widest gap is in drugs: osimertinib is reimbursed in China at $24 a tablet (165.54 yuan), about $710 a month, against a US list price near $18,000 a month [1][2][3]. The catch, and it is a large one: that Chinese figure is the insured price, and a foreign patient paying cash does not automatically get it [1].
Key takeaways
- Cancer costs are quoted per phase, not per disease: surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy each behave differently [4].
- China's price advantage is largest in drugs and smallest in surgery, because drug prices were cut by national negotiation and surgery was never the expensive part [1].
- The headline drug price is usually the reimbursed price for a Chinese insured resident, not the cash price offered to a foreign patient [1].
- Stage at diagnosis changes the total more than the country does. Early-stage surgery is a bounded cost; stage IV is an open-ended one [4].
- What you cannot buy at any price is continuity: pathology re-review, imaging comparison and the clinician who knows your case [5].
Why “the cost of cancer” is not a number
Two patients with the same diagnosis can differ tenfold in cost, for reasons that have nothing to do with the hospital: stage at diagnosis, the mutation profile, whether surgery is possible, how many lines of systemic therapy are used, and how long treatment continues.
So this article does what price pages should do: it breaks the episode into phases, gives the range for each, and says which of those ranges a foreign patient can actually reach.
Cost by phase
| Phase | China, cash price | US list price |
|---|---|---|
| Diagnosis: CT, PET-CT, bronchoscopy, biopsy, genomic panel | $700–2,900 (5,000–20,000 yuan) | $5,000–25,000 |
| Lobectomy (VATS) | $4,300–11,400 (30,000–80,000 yuan) | $35,000–100,000 |
| Chemotherapy, per cycle | $430–1,430 (3,000–10,000 yuan) | $5,000–15,000 |
| Radiotherapy, full course | $1,400–4,300 (10,000–30,000 yuan) | $12,000–60,000 |
| Targeted therapy, per month | From about $710 insured; higher on cash | $15,000–21,000 |
| Immunotherapy, per year | Domestic PD-1 products are far cheaper than imported ones | $120,000–200,000 |
Chinese ranges are compiled from published hospital price information and consumer health guides; they are not a national tariff, and they exclude complications. US figures are list prices before insurance, which almost nobody pays in full [3].
The drug gap is where the money is
Since the national medical insurance negotiations began in 2016, oncology drugs have been the centrepiece. Osimertinib, the standard first-line EGFR inhibitor, illustrates the scale: the reimbursed price in China is 165.54 yuan per 80 mg tablet, or about 4,966 yuan a month [1]. The US list price for the same drug is roughly $18,000–21,000 a month [2].
The caveat that matters. 165.54 yuan is the price the insurance scheme pays, for a patient inside the scheme, for an indication on the reimbursement list. A foreign patient paying cash at an international department is quoted a hospital price, which is typically higher, and eligibility still has to match the approved indication. Ask for the cash price in writing, per box, with the dosage, before you budget anything.
The same pattern applies across the catalogue: imported PD-1 inhibitors are expensive everywhere, while China's domestic PD-1 products have pushed prices down sharply inside the country. That is a genuine advantage — but only for products and indications that are registered in China [1].
Breast cancer: a shorter version of the same story
Breast cancer behaves differently because the treatment path is driven by receptor status (ER, PR, HER2) rather than by stage alone. That produces three quite different budgets: endocrine therapy, which is cheap and taken for years; chemotherapy, which is bounded; and HER2-directed therapy, which is where the cost concentrates.
We are not publishing a Chinese price range for trastuzumab or pertuzumab here, because we could not verify a cash price for foreign patients at the time of writing. What we can tell you is what to ask: whether the biosimilar or the originator is being used, whether the quote is per cycle or per year, and whether cardiac monitoring is included, since HER2 therapy requires it.
The condition in context: what determines the outcome
For lung cancer, five-year survival is driven mainly by stage at diagnosis, then by whether the tumour carries an actionable driver mutation, then by whether surgery is technically possible, and only then by which hospital you chose.
For breast cancer, the drivers are receptor status, stage, and whether treatment follows the guideline sequence — surgery, then systemic therapy, then radiotherapy, in the order the biology requires.
None of these is bought with money. What money buys is access: to genomic testing, to the right drug, to a surgeon who operates often enough, and to a team that meets to discuss your case.
What the price does not buy
- Pathology re-review. Every cross-border cancer case should have the slides re-read at the treating centre. Ask whether that is included.
- Genomic testing of sufficient breadth. A five-gene panel and a 500-gene panel lead to different treatment options.
- A multidisciplinary meeting. Ask whether your case will be discussed, and whether you get a written summary.
- Continuity. If you start chemotherapy in China and go home, someone has to own the next cycle. This is the most common failure point.
- Trial access. Trials have eligibility rules and nationality requirements; wanting in is not enough.
When not to come
| Situation | Why |
|---|---|
| You are mid-course on systemic therapy at home | Interrupting a regimen to travel is usually worse than finishing it |
| You need a drug not registered in China | Access is limited to the Hainan special-permission route, product by product |
| Your disease is progressing on treatment | You need a trial or a new line, not a flight |
| You cannot return for follow-up imaging | Response assessment requires the same scanner and the same radiologist |
| You want a guarantee | No centre in any country can give one |
Decision checklist
| Question | If yes |
|---|---|
| Do I know my stage, histology and mutation status? | You can be quoted properly [4] |
| Will the centre re-read my pathology? | Baseline for any decision |
| Is the drug I need registered in China for my indication? | Otherwise it is a different plan [1] |
| Have I been quoted a cash price, per cycle, in writing? | Budgetable |
| Do I have an oncologist at home for continuation? | Essential |
Availability and limits
- Chinese ranges come from published hospital price information, not from a national tariff; they exclude complications and supportive care.
- The reimbursed drug price cited is for insured Chinese residents and does not automatically apply to foreign self-payers [1].
- US figures are list prices before insurance and are not what insured patients pay [3].
- Survival depends on stage, biology and adherence to guidelines, not on the country of treatment [4][5].
- We are not a provider and do not book treatment.
What to ask before booking
| Question | Why it matters |
|---|---|
| What is the cash price per cycle, including pre-medication and antiemetics? | The advertised price is rarely the billed price. |
| Is the drug the originator or a domestic equivalent, and is either registered for my indication? | Changes both price and legality [1]. |
| Which department handles foreign patients, and in what language? | We do not book treatment; confirm the international department and its language support. |
| Who reviews my scans between cycles? | Response assessment must be consistent. |
| If I have a febrile neutropenia episode at night, where do I go? | This is the emergency that actually happens. |
Questions patients ask
How much does lung cancer treatment cost in China?
By phase: a lobectomy is commonly quoted at $4,300-11,400, a chemotherapy cycle at $430-1,430, and a radiotherapy course at $1,400-4,300. Drug costs depend on the drug and on whether you pay the reimbursed or the cash price [1][3].
Why is osimertinib so much cheaper in China?
Because it was included in national insurance negotiations, which set the reimbursed price at 165.54 yuan per tablet, about $710 a month. That price applies to insured residents within the approved indication; a foreign cash payer is quoted a hospital price, which is higher [1].
Can I get the same drugs as in the US?
Only if the product is registered in China for your indication. Otherwise access runs through the Hainan special-permission route, product by product, or through a clinical trial [1].
How long do I need to stay?
Surgery typically means two to three weeks including pre-operative workup. Chemotherapy is given in cycles every two to three weeks, which can sometimes be continued at home if a local oncologist agrees to take over.
Is treatment in China cheaper overall?
Usually, and mostly because of drug prices rather than surgery. But the total depends on stage and the number of lines of therapy, so compare a written plan with prices per phase, not a headline figure.